Alexandra L. Thomas
Northwestern University
6 Papers
16 Citations
Alexandra L. Thomas is an academic researcher from Northwestern University. The author has contributed to research in topics: Phosphorylation & Cyclin-dependent kinase. The author has an hindex of 6, co-authored 6 publications. Previous affiliations of Alexandra L. Thomas include University of Michigan.
Chat about Author
Papers
Maternal short-chain fatty acids are associated with metabolic parameters in mothers and newborns.
Medha Priyadarshini,Alexandra L. Thomas,Anna C. Reisetter,Denise M. Scholtens,Thomas M.S. Wolever,Jami L. Josefson,Brian T. Layden,Brian T. Layden +7 more
TL;DR: Novel relationships exist among maternal SCFA levels and multiple interrelated maternal/newborn metabolic parameters, and serum acetate levels were associated with maternal weight gain and maternal adiponectin levels.
91
Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.
Alexandra L. Thomas,Cristian Coarfa,Jun Qian,Joseph J. Wilkerson,Joseph J. Wilkerson,Kimal Rajapakshe,Nancy L. Krett,Preethi H. Gunaratne,Steven T. Rosen +8 more
TL;DR: This research has verified two targets, namely RRM2 and BCL2L1, as primary functional targets of GR involved in GC-induced cell death, and integrated data sets to identify a subset of candidate genes that may form the basis for a comprehensive picture of glucocorticoid actions in multiple myeloma.
19
Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells
Joseph T. Decker,Eric C. Hobson,Yining Zhang,Seungjin Shin,Alexandra L. Thomas,Jacqueline S. Jeruss,Kelly B. Arnold,Lonnie D. Shea +7 more
TL;DR: The identification of NOTCH signaling as a common pathway contributing to PARP inhibitor resistance by TRACER indicates the efficacy of transcription factor dynamics in identifying targets for intervention in treatment‐resistant cancer and provides a new method for determining effective strategies for directed chemotherapy.
19
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Shreyas S. Rao,Jenna R. Stoehr,Danijela Dokic,Lei Wan,Joseph T. Decker,Kristine E. Konopka,Alexandra L. Thomas,Jia Wu,Virginia G. Kaklamani,Lonnie D. Shea,Lonnie D. Shea,Jacqueline S. Jeruss +11 more
TL;DR: The potential of this novel drug combination, CYC065 and eribulin, to suppress the growth of TNBC cells in vitro and in vivo is highlighted, warranting further clinical investigation.
Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells
Alexandra L. Thomas,Hanne Lind,Angela Hong,Danijela Dokic,Kailey Oppat,Elana Rosenthal,Amina Guo,Aaron Thomas,Randala Hamden,Jacqueline S. Jeruss +9 more
TL;DR: The data show that the Pin1-Smad3 interaction, facilitated by CDK-mediated Smad3 phosphorylation, is associated with oncogenic TGFβ signaling and breast cancer progression.